Holen Sie sich die Stockscreener-App
0.6883
4.29%
0.0283
Handel nachbörslich:
.68
-0.0083
-1.21%
Schlusskurs vom Vortag:
$0.66
Offen:
$0.652
24-Stunden-Volumen:
87,627
Relative Volume:
0.51
Marktkapitalisierung:
$1.06M
Einnahmen:
$743.00K
Nettoeinkommen (Verlust:
$-7.63M
KGV:
-0.2294
EPS:
-3
Netto-Cashflow:
-
1W Leistung:
+0.42%
1M Leistung:
-33.50%
6M Leistung:
-54.42%
1J Leistung:
-73.01%
1-Tages-Spanne:
$0.6501
$0.6883
1-Wochen-Bereich:
$0.6501
$0.7031
52-Wochen-Spanne:
$0.632
$3.12
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Firmenname
Can-Fite Biopharma Ltd ADR
Sektor
Branche
Telefon
972 3 924 1114
Adresse
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Vergleichen Sie CANF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.6883 | 10.15M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-10-19 | Fortgesetzt | ROTH Capital | Buy |
| 2016-08-29 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2015-11-30 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-31 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Bestätigt | ROTH Capital | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Can-Fite Biopharma Ltd ADR Aktie (CANF) Neueste Nachrichten
What indicators show strength in Enterprise Products Partners L.P. Limited PartnershipIn-Depth Stock Trading Volume Analysis - Newser
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial By Investing.com - Investing.com South Africa
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs By Investing.com - Investing.com India
Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo Finance
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
Finanzdaten der Can-Fite Biopharma Ltd ADR-Aktie (CANF)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):